Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
The cancer is particularly difficult to treat with traditional therapies.
New results confirm that the drug, Balversa (erdafitinib), can benefit people whose tumors have a certain genetic alteration.
“The bladder cancer research community pulled together to get this trial done,” says principal investigator Thomas Flaig, MD.
More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.
HIV-positive individuals are also diagnosed with cancer at later stages than those without the virus.
Balversa led to tumor regression in about a third of patients with susceptible genetic mutations.
Here’s a list of the approved drugs to treat bladder cancer. Click on any of the medications for more info on indications, dosing and...
Mental health care before cancer treatment is associated with higher death rates for those with kidney, prostate or bladder cancer.
NKTR-214 plus Opdivo as first-line therapy had an overall response rate of 48 percent.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.